Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular
Free webinar: Telepathology: is there added value in LMICs?
Free webinar: Telepathology: is there added value in LMICs?

Tackling the increase in cancer cases worldwide

Dr Eduardo Cazap and Prof Tezer Kutluk
Tackling the increase in cancer cases worldwide ( Dr Eduardo Cazap and Prof Tezer Kutluk )
21 Jun 2019

Getting high level care to low and middle income countries

Dr Eduardo Cazap, Dr Clifford Hudis
Getting high level care to low and middle income countries ( Dr Eduardo Cazap, Dr Clifford Hudis )
21 Jun 2019

How will ASCO combat cancer disparities?

Dr Eduardo Cazap, Dr Richard Schilsky
How will ASCO combat cancer disparities? ( Dr Eduardo Cazap, Dr Richard Schilsky )
21 Jun 2019

Chemotherapy-free strategies in treating leukaemia

Prof Robin Foa - University of Rome, Rome, Italy
Chemotherapy-free strategies in treating leukaemia ( Prof Robin Foa - University of Rome, Rome, Italy )
20 Jun 2019

Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-positive ALL patients

Prof Robin Foa - University of Rome, Rome, Italy
Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-positive ALL patients ( Prof Robin Foa - University of Rome, Rome, Italy )
20 Jun 2019

Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL

Prof Max Topp - University of Würzburg, Würzburg, Germany
Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL ( Prof Max Topp - University of Würzburg, Würzburg, Germany )
20 Jun 2019

ADMIRAL trial results: Gilteritinib versus salvage chemotherapy in patients with FLT3-mutated relapsed/refractory AML

Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA
ADMIRAL trial results: Gilteritinib versus salvage chemotherapy in patients with FLT3-mutated relapsed/refractory AML ( Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA )
20 Jun 2019

CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy

Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany
CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy ( Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany )
20 Jun 2019

Multiple myeloma science from EHA 2019

Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France
Multiple myeloma science from EHA 2019 ( Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France )
20 Jun 2019

CAR T-cell therapy for treating acute leukaemia

Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France
CAR T-cell therapy for treating acute leukaemia ( Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France )
20 Jun 2019

Selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia

Prof Walter Fiedler - University of Hamburg, Hamburg, Germany
Selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia ( Prof Walter Fiedler - University of Hamburg, Hamburg, Germany )
20 Jun 2019

Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy for MM

Dr Heng Mei - Huazhong University of Science and Technology, Wuhan, China
Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy for MM ( Dr Heng Mei - Huazhong University of Science and Technology, Wuhan, China )
20 Jun 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation